A unique monoclonal protein, Pritoxaximab – formerly known as DXX00601 – shows significant opportunity in the management of severe hemolytic reaction (TRALI). Created by Bio-X, Pritoxaximab functions by https://www.targetmol.com/compound/pritoxaximab